Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
autologous T cell memory cells (1 trial)
doxorubicin (Doxil) (1 trial)
epirubicin (ellence) (1 trial)
paclitaxel (taxol) (1 trial)
tislelizumab (1 trial)
toripalimab (LOQTORZ) (1 trial)
Breast Neoplasms (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Trials (3 total)
Trial APIs (6 total)